Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lung cancer drug under the microscope: how does tislelizumab work in real life?

NCT ID NCT07510724

First seen Apr 05, 2026 · Last updated Apr 30, 2026 · Updated 3 times

Summary

This study is observing how lung cancer patients fare when treated with the immunotherapy drug Tislelizumab in everyday clinics, not just in controlled trials. Researchers will track survival, treatment patterns, side effects, and quality of life in 240 participants across Germany and Austria. The goal is to understand how well the drug works outside of strict research settings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Krankenhaus Nordwest

    RECRUITING

    Frankfurt am Main, Hesse, 60488, Germany

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • Universitätsklinikum St. Pölten - Lilienfeld, Karl Landsteiner Privatuniversität für Gesundheitswissenschaften

    NOT_YET_RECRUITING

    Sankt Pölten, Lower Austria, 3100, Austria

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.